Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Mayne Pharma Group Limited
  6. News
  7. Summary
    MYX   AU000000MYX0

MAYNE PHARMA GROUP LIMITED

(MYX)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Mayne Pharma : Adds New Products to Australian Dermatology Portfolio

06/20/2021 | 11:13pm EDT


© MT Newswires 2021
All news about MAYNE PHARMA GROUP LIMITED
10:09aMAYNE PHARMA : Fda approves lexetteo for adolescent plaque psoriasis
AQ
09/21MAYNE PHARMA : 22/09/2021 FDA Approves Lexette® for Adolescent Plaque Psoriasis
PU
09/21U.S. Food and Drug Administration Approves Mayne Pharma LEXETTE for Adolescent Plaque P..
CI
09/02MAYNE PHARMA : Change of Director's Interest Notice
PU
08/27MAYNE PHARMA : 2021 Full Year Media Release
PU
08/27MAYNE PHARMA : 2021 Full Year Investor Presentation
PU
08/27MAYNE PHARMA : Appendix 4E and Statutory Accounts
PU
08/27MAYNE PHARMA : Widens Net Loss in FY21 on Higher Impairments
MT
08/26MAYNE PHARMA : 27/08/2021 Mayne Pharma 2021 Full Year Results Media Release
PU
08/26Mayne Pharma Group Limited Reports Earnings Results for the Full Year Ended June 30, 20..
CI
More news
Financials
Sales 2022 463 M 335 M 335 M
Net income 2022 -26,1 M -18,9 M -18,9 M
Net Debt 2022 259 M 187 M 187 M
P/E ratio 2022 -14,7x
Yield 2022 -
Capitalization 503 M 365 M 364 M
EV / Sales 2022 1,65x
EV / Sales 2023 1,34x
Nbr of Employees 967
Free-Float 77,2%
Chart MAYNE PHARMA GROUP LIMITED
Duration : Period :
Mayne Pharma Group Limited Technical Analysis Chart | MYX | AU000000MYX0 | MarketScreener
Technical analysis trends MAYNE PHARMA GROUP LIMITED
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 0,29 AUD
Average target price 0,45 AUD
Spread / Average Target 56,3%
EPS Revisions
Managers and Directors
Scott Richards Chief Executive Officer, MD & Executive Director
Peter Paltoglou Chief Financial Officer
Roger Campbell Corbett Independent Non-Executive Chairman
Gerard G. Nahum Chief Medical Officer
Keith Moore Vice President-Research & Development